ASPG and acute lymphoblastic leukemia: For medicines used almost exclusively for the treatment of paediatric ALL, asparaginase and 6-mercaptopurine, the volume sold is more than sufficient (2.3 and 1.5 times, respectively, the amounts needed) to treat all children diagnosed with ALL, including children who relapse.